A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH)
Latest Information Update: 10 Aug 2026
At a glance
- Drugs Amrecibart (Primary) ; Cenvacibart (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms ROXI-CATH
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 13 Apr 2026 Status changed from active, no longer recruiting to completed.
- 12 Jan 2026 Planned End Date changed from 8 Jun 2026 to 1 Jun 2026.
- 12 Jan 2026 Planned primary completion date changed from 8 Jun 2026 to 1 Jun 2026.